Michael E Weinblatt Selected Research

Rheumatoid Arthritis

3/2024	Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
12/2023	Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
12/2023	Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
2/2023	Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case-control study.
1/2023	Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis.
1/2023	Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.
10/2022	Serum proteomic profiling of rheumatoid arthritis-interstitial lung disease with a comparison to idiopathic pulmonary fibrosis.
4/2022	Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.
4/2022	The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity.
1/2022	Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael E Weinblatt Research Topics

Disease

125	Rheumatoid Arthritis 03/2024 - 03/2002
16	Infections 01/2021 - 11/2003
9	Pain (Aches) 12/2023 - 04/2013
9	Rheumatic Diseases (Rheumatism) 06/2023 - 03/2009
9	Arthritis (Polyarthritis) 06/2023 - 05/2002
7	Fatigue 12/2023 - 04/2013
6	Inflammation (Inflammations) 01/2019 - 01/2010
5	Gout 08/2023 - 01/2021
4	COVID-19 03/2023 - 06/2022
4	Heart Failure 01/2021 - 08/2008
4	Neoplasms (Cancer) 01/2017 - 05/2006
3	Interstitial Lung Diseases (Interstitial Lung Disease) 02/2023 - 06/2015
3	Venous Thromboembolism 12/2021 - 01/2019
3	Psoriatic Arthritis 11/2018 - 04/2003
3	Disease Progression 01/2018 - 05/2004
3	Injection Site Reaction 08/2015 - 01/2013
2	Chronic Disease (Chronic Diseases) 12/2023 - 11/2017
2	Lung Diseases (Lung Disease) 01/2021 - 01/2021
2	Liver Diseases (Liver Disease) 01/2021 - 01/2021
2	Rheumatoid Nodule 01/2021 - 01/2019
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2021 - 01/2021
2	Necrosis 01/2020 - 11/2018
2	Dyspnea (Shortness of Breath) 03/2019 - 07/2014
2	Hypersensitivity (Allergy) 11/2018 - 11/2018
2	Myositis (Idiopathic Inflammatory Myopathies) 08/2008 - 05/2006
1	Joint Diseases (Joint Disease) 08/2023
1	COVID-19 rebound 03/2023
1	Obesity 02/2023
1	Melanoma (Melanoma, Malignant) 01/2023
1	Gouty Arthritis 01/2023
1	Skin Neoplasms (Skin Cancer) 01/2023

Drug/Important Bio-Agent (IBA)

50	Methotrexate (Mexate)FDA LinkGeneric 08/2023 - 03/2002
21	Antirheumatic Agents (DMARD)IBA 03/2024 - 05/2004
21	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 01/2003
17	brassIBA 01/2022 - 01/2006
15	Adalimumab (Humira)FDA Link 04/2022 - 01/2003
10	Monoclonal AntibodiesIBA 10/2022 - 01/2003
10	Etanercept (Enbrel)FDA Link 01/2020 - 05/2002
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2011
8	Tumor Necrosis Factor InhibitorsIBA 01/2020 - 09/2008
7	GlucocorticoidsIBA 02/2023 - 06/2007
7	C-Reactive ProteinIBA 01/2021 - 02/2011
7	Rheumatoid FactorIBA 01/2020 - 01/2008
6	AutoantibodiesIBA 02/2023 - 10/2008
6	Anti-Citrullinated Protein AntibodiesIBA 02/2023 - 05/2009
6	Abatacept (Orencia)FDA Link 04/2022 - 01/2013
6	fostamatinibIBA 01/2018 - 02/2011
6	Syk KinaseIBA 12/2014 - 11/2008
5	Pegloticase FDA Link 08/2023 - 01/2021
5	Infliximab (Remicade)FDA Link 01/2020 - 12/2005
4	tofacitinibIBA 12/2023 - 06/2018
4	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2023 - 09/2013
4	ametantrone (HAQ)IBA 08/2023 - 04/2015
4	Uric Acid (Urate)IBA 08/2023 - 01/2022
4	Proteins (Proteins, Gene)FDA Link 02/2023 - 03/2012
4	Biosimilar PharmaceuticalsIBA 01/2020 - 01/2018
4	golimumab FDA Link 01/2018 - 03/2013
4	Certolizumab Pegol FDA Link 10/2017 - 12/2012
3	Rituximab (Mabthera)FDA Link 06/2023 - 05/2006
3	AntigensIBA 03/2023 - 08/2010
3	AntibodiesIBA 02/2023 - 04/2003
3	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2023 - 12/2021
3	cyclic citrullinated peptideIBA 01/2022 - 05/2009
3	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2019 - 06/2003
3	baricitinibIBA 01/2019 - 01/2017
3	Interleukin-17 (Interleukin 17)IBA 11/2018 - 11/2018
3	mavrilimumabIBA 01/2018 - 09/2013
2	Janus Kinase InhibitorsIBA 12/2023 - 06/2018
2	OtilimabIBA 12/2023 - 12/2023
2	COVID-19 VaccinesIBA 06/2023 - 06/2022
2	Prednisone (Sone)FDA LinkGeneric 06/2023 - 05/2006
2	Immunologic Factors (Immunomodulators)IBA 03/2023 - 10/2022
2	ORALIT (ORS)IBA 12/2022 - 06/2022
2	EpitopesIBA 04/2022 - 10/2010
2	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2019
2	Peptides (Polypeptides)IBA 01/2021 - 03/2012
2	Collagen Type I (Type I Collagen)IBA 01/2019 - 01/2018
2	ABT-122IBA 11/2018 - 11/2018
2	CollagenIBA 01/2018 - 01/2010
2	HDL LipoproteinsIBA 12/2016 - 01/2015
2	HDL CholesterolIBA 12/2016 - 01/2015
2	LDL Lipoproteins (beta Lipoproteins)IBA 12/2016 - 01/2015
2	LDL CholesterolIBA 12/2016 - 01/2015
2	3-benzoyl dopamine (MBDA)IBA 04/2016 - 01/2013
2	LipidsIBA 01/2015 - 05/2010
2	tocilizumab (atlizumab)FDA Link 03/2013 - 07/2011
2	Immunoglobulin G (IgG)IBA 03/2012 - 08/2010
2	CytokinesIBA 04/2011 - 06/2003
2	EnzymesIBA 05/2010 - 04/2003
1	sarilumabIBA 12/2023
1	Macrophage Colony-Stimulating FactorIBA 12/2023
1	Messenger RNA (mRNA)IBA 06/2023
1	VaccinesIBA 06/2023
1	cilgavimab and tixagevimab drug combinationIBA 06/2023
1	mRNA VaccinesIBA 06/2023
1	nirmatrelvir and ritonavir drug combinationIBA 10/2022

Therapy/Procedure

34	Therapeutics 12/2023 - 05/2002
3	Biological Therapy 11/2019 - 02/2011
2	Aftercare (After-Treatment) 03/2023 - 01/2023
2	Ambulatory Care (Outpatient Care) 01/2013 - 04/2002